Aybintio (abaloparatide)
Aybintio is a prescription medicine used to treat osteoporosis in postmenopausal women at high risk for fracture.
The active ingredient in Aybintio is abaloparatide, a synthetic peptide analog of human PTHrP
Aybintio is administered by subcutaneous injection once daily.
Routes of Administration
Subcutaneous injection
The recommended dose of Aybintio is 80 mcg administered subcutaneously once daily.
Strength
Aybintio is available in a strength of 80 mcg/1 mL.
The recommended dose of Aybintio is 80 mcg administered subcutaneously once daily in the thigh, abdomen or upper arm.
Solution for injection
Aybintio is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
Aybintio is contraindicated in patients with a history of hypersensitivity to abaloparatide or any of its components.
composition
Aybintio contains abaloparatide, a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP).
Packaging
Each pre-filled syringe of Aybintio contains 80 mcg of abaloparatide in 1 mL of solution.
Storage conditions
Aybintio should be stored in the refrigerator at a temperature of 2°C to 8°C (36°F to 46°F).
Sale terms
Prescription Only Medicine
Telephone
(866) 321-8727
The most common side effects of Aybintio include hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, and vertigo.
Aybintio should be administered by a healthcare professional. Patients should be advised to increase their calcium and vitamin D intake during treatment with Aybintio.
In the event of an overdose, patients should seek medical attention immediately.
There are no known drug interactions with Aybintio.
ATC Code
Expiry date
Price Range
Bone Metabolism Regulator
Parathyroid Hormones and Analogues
Aybintio increases bone formation by stimulating osteoblasts and inhibiting osteoclasts.
Abaloparatide is rapidly absorbed following subcutaneous injection with a mean Tmax of 0.5 to 1 hour. The absolute bioavailability of abaloparatide is approximately 45%.
Aybintio was evaluated in a phase 3 randomized, double-blind, placebo-controlled study in postmenopausal women with osteoporosis. Treatment with Aybintio for 18 months significantly reduced the risk of vertebral, nonvertebral, and major osteoporotic fractures compared to placebo.
Postmenopausal women with osteoporosis
Treatment with Aybintio for 18 months significantly reduced the risk of vertebral, nonvertebral, and major osteoporotic fractures compared to placebo.
